Inflammatory Bowel disease: Short- and long- term treatments

Disease-a-Month

Volumn 44, Issue 4, 1998, Pages 144-172

  Bickston, Stephen J ^a   Cominelli, Fabio ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOTROPIN; CYCLOSPORIN; FISH OIL; FOLIC ACID; GLUCOCORTICOID; HEPARIN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PREDNISONE; RECOMBINANT CYTOKINE; SALAZOSULFAPYRIDINE; TRACE ELEMENT;

ANTIBIOTIC THERAPY; CROHN DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; PARENTERAL NUTRITION; REVIEW; ULCERATIVE COLITIS;

EID: 0031900824     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(98)90008-6     Document Type: Review

References (150)

1. Waye JD: Endoscopy in inflammatory bowel disease, in Kirsner JD, Shorter RG (eds): Inflammatory Bowel Disease. Philadelphia, Lea & Febiger 1988, pp 353-376.
2. Truelove SC, Witts LJ: Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 2:1041-1045, 1955.
3. Morrison LM: Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology 21:133-138, 1952.
4. Nielsoen OH, Andreasson B, Bondesen S, et al: Pregnancy in ulcerative colitis. Scand J Gastroenterol 18:735-742, 1983.
5. Jarnerot G, Into-Malberg MB: Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 14:869-871, 1979.
6. Misiewicz JJ, Leonard-Jones JE, Conell AM, et al: Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1:185-188, 1965.
7. Klotz U, Maier KE: Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci 32:46S-50S, 1987.
8. Sutherland LR, Martin F, Greer S, et al: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894-1898, 1987.
9. Campieri M, Lanfranchi CA, Brignola C, et al: Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 29:108, 1986.
10. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118:540-549, 1993.
11. Peppercorn MA: Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 17:14-27, 1993.
12. Chapman RW, Selbt WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27:1210-1212, 1986.
13. Mantzaris GJ, Hatzis A, Kontogiannis P, et al: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89:43-46, 1994.
14. Gilat T, Suissa A, Leichtman G, et al: A comparative study of metronidazole in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9:415-417, 1987.
15. Gilat T, Leichtman G, Delpre G, et al: A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11:392-395, 1989.
16. Turunen U, Farkkila M, Hakala K, et al: A double-blind, placebo controlled six-month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology 106:786A, 1994.
17. Tawfik AF, Shoeb HA, Bishop SJ, et al: Influence of new quinolones on normal immune capabilities. J Chemother 2:300-305, 1990.
18. Kornbluth AA, Salomon P, Sacks HS, et al: Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 16:215-218, 1993.
19. Leaonard-Jones JE, Longmore AJ, Newell AC, et al: Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1:188-189, 1965.
20. Campieri M, Gionhetti P, Belluzzi A, et al: Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 32:67S-70S, 1987.
21. Rosenberg W, Ireland A, Jewell D: High-dose methylprednisone in the treatment of active ulcerative colitis. J Clin Gastroenterol 12:40-41, 1990.
22. Meyer S, Sachat DB, Goldberg JD, et al: Corticotropin versus hydrocortisone in intravenous treatment of ulcerative colitis. Gastroenterology 85:351-357, 1983.
23. Spencer CM, McTavish D: Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50:854-872, 1995.
24. Lemann M, Galian A, Rutgeerts P, et al: Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 9:557-562, 1995.
25. Lofberg R, Ostergaard TO, Langholz E: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 8:623-629, 1994.
26. Anonymous: Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol 26:1225-1230, 1991.
27. Adler DJ, Korelitz BI: The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85:717-722, 1990.
28. O'Connell WR, Kamm MA, Ritchie JK, et al: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34:1081, 1983.
29. Haber CJ, Meltzer SJ, Present DH, et al: Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 91:982-986, 1986.
30. Shorey J, Schenker S, Suki WN: Hepatotoxicity of mercaptopurine. Arch Intern Med 122:54-58, 1968.
31. Kinlen LJ: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78:44-49, 1985.
32. Connell WR, Kamm MA, Dickson M, et al: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249-1252, 1994.
33. Atherton LD, Leib ES, Kaye MD: Toxic megacolon associated with methotrexate therapy. Gastroentero]ogy 86:1583-1588, 1984.
34. Kozarek RA, Patterson DJ, Gelland MD, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110:353-356, 1989.
35. Baron TH, Truss CD, Elson CO: Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 38:1851-1856, 1993.
36. Oren R, Arber N, Odes S, et al: Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 110:1416-1421, 1996.
37. Winter TA, Dalton HR, Merrett MN, et al: Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis.' Scand J Gastroenterol 28:701-704, 1993.
38. Sandborn WL, Tiemaine WJ, Schroeder KW, et al: Cyclosporine enemas for treatment-resistant, mildly to moderately active left-sided ulcerative colitis. Am J Gastroenterol 88:640-645, 1993.
39. Sandborn WJ, Tremaine WJ, Schroeder KW, et al: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106:1429-1435, 1994.
40. Lichtiger S, Present DH: Preliminary report: Cyclosporine in treatment of severe active ulcerative colitis. Lancet 336:16, 1990.
41. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841-1845, 1994.
42. Stephens L, Goldstein R, Grippin J, et al: Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 25:1122-1123, 1993.
43. Talbot RW, Heppell J, Dosois RR, et al: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 61:140-145, 1986.
44. Gaffney PR, O'Leary JL, Doyle CT, et al: Response to heparin in patients with ulcerative colitis. Lancet 337:238-239, 1991.
45. Silverstein MD, Lashnet BA, Hanauer SB: Cigarette smoking and ulcerative colitis: A case-control study. Mayo Clin Proc 69:425-429, 1994.
46. Pullan RD, Rhodes J, Ganesh S, et al: Transdermal nicotine for ulcerative colitis. N Engl J Med 330:811-815, 1994.
47. Thomas GA, Rhodes J, Mani B, et al: Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 332:988-992, 1995.
48. Sandborn SJ, Tremaine MD, Offord KP, et al: Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126:364-371, 1997.
49. Zijlstra FJ, Srivastava ED, Rhodes M, et al: The effect of nicotine on rectal mucus and mucosal eicosanoids. Gut 35:247-251, 1994.
50. Pullan RD: Colonic mucus, smoking and ulcerative colitis. Ann R Coll Surg Engl 78:85-91, 1996.
51. Van Dijk JP, Madretsma GS, Keuskamp ZJ, et al: Nicotine inhibits cytokine synthesis by mouse colonic mucosa. Eur J Pharmacol 278:R11-R12, 1995.
52. Gonzales-Huix F, Fernandez-Banares F, Esteve-Comas M, et al: Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 88:227-232, 1993.
53. Dickinson RL, Ashton MG, Axon AT, et al: Controlled trial of intravenous hyperal-imentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 79:1199-1204, 1980.
54. McIntyre PB, Powell-Tuck J, Wood SR, et al: Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 27:481-485, 1986.
55. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al: Enteral versus parenteral nutrition as an adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 88:227-232, 1993.
56. Greenfield SM, Green AT, Teare JP, et al: A randomized controlled study of evening primrose and fish oil in ulcerative colitis. Aliment Pharmacol Ther 7:159-166, 1993.
57. Salomon P, Kornbluth AA, Janowitz HD: Treatment of ulcerative colitis with fish oil n-3 omega-fatty acid: An open trial. J Clin Gastroenterol 12:157-161, 1990.
58. Aslan A, Triadafilopoulos G: Fish oil fatty acid supplementation inactive ulcerative colitis: A double-blind, placebo-controlled, crossover study. Am J Gastroenterol 87:432-437, 1992.
59. Stenson WF, Cort D, Rodgets J, et al: Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116:609-614, 1992.
60. Ormerod TP: Observations on the incidence and cause of anaemia in ulcerative colitis. Gut 8:107-114, 1967.
61. Halsted CH, Gandhi G, Tamura T: Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 305:1513-1517, 1981.
62. Lashnet BA: Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 119:549-554, 1993.
63. Lashher BA, Heidenreich PA, Su GL, et al: Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 97:255-259, 1989.
64. Ringstad J, Kiledebo S, Thomassen Y: Serum selenium, copper, and zinc concentrations in Crohn's disease and ulcerative colitis. Scand J Gatstroenterol 28:605-608, 1993.
65. Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin). Gut 14:923-926, 1973.
66. Azad Khan AK, Piris J, Truelove SC, et al: Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 21:232-240, 1980.
67. Franklin JL, Rosenberg IH: Impaired folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (Azulfidine). Gastroenterology 64:517-525, 1973.
68. Rijk MC, van Lier HJ, van Tongetch JH, et al: Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission. A double-blind, randomized, multicenter study. Am J Gastroenterol 87:438-442, 1992.
69. Riley SA, Mani V, Goodman MJ, et al: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 94:1383-1389, 1988.
70. Biddle WL, Greenberger NJ, Swan JT, et al: 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 94:1075-1079, 1988.
71. Miner P, Daly R, Nester T, et al: The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 106:736A, 1994.
72. D'Arenzo AA, Panarese AA, D'Armiento FP, et al: 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis. Dis Colon Rectum 5:395-397, 1990.
73. Hawthorne AB, Logan RFA, Hawkey CJ, et al: Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305:20-22, 1992.
74. George J, Present DH, Pou R, et al: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91:1711-1714, 1996.
75. Summers RW, Switz DM, Sessions JT, et al: National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 77:847-869, 1979.
76. Malchow H, Ewe K, Brandes JW, et al: European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 86:249-266, 1984.
77. Singleton JW, Summers RW, Kern F, et al: A trial of sulfasalazine as adiunctive therapy in Crohn's disease. Gastroenterology 77:887-897, 1979.
78. Dalziel TK: Chronic intestinal enteritis. BMJ 2:1068, 1913.
79. Crohn BB, Ginzberg I, Oppenheimer G: Regional ileitis: A pathologic and clinical entity. JAMA 99:1323, 1932.
80. Fidler HM, Thurrell W, Johnson NM, et al: Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease. Gut 35:506, 1994.
81. Liu Y, van Kruiningen HJ, West AB, et al: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108:1396, 1995.
82. Sutherland L, Singleton J, Sessions J, et al: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32:1071-1075; 1991.
83. Ursing B, Aim T, Barany F, et al: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. Gastroenterology 83:550-562, 1982.
84. Grove DI, Mahmoud AA, Warren KS: Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 54:422-427, 1977.
85. Markowitz JF, Silverberg M: Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 88:681-684, 1985.
86. Prantera C, Koh A, Zannoni F, et al: Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: Results of an open study. J Clin Gastroenterol 19:79-88, 1994.
87. Salomon P, Kornbluth AA, Aisenberg J, et al: How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 12:211-215, 1992.
88. Singleton JW, Law DH, Kelley ML, et al: National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology 77:870-882, 1979.
89. Vakil N, Sparberg M: Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 96:62-67, 1989.
90. Rutgeerts P, Lofberg R, Malchow H, et al: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842-845, 1994.
91. Present DH, Korelitz BI, Wisch N, et al: Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302:981-987, 1980.
92. Colonna T, Korelitz BI: The role of leucopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 89:362-366, 1994.
93. Sandborn WJ, Van O EC, Zins BJ, et al: An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109:1808-1817, 1995.
94. Kozarek PA, Patterson DJ, Gelfland MD, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110:353-356, 1989.
95. Baron TH, Truss CD, Elson CO: Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 38:1851-1856, 1993.
96. Feagan BG, Rochon J, Fedorak RN, et al: Methotrexate for the treatment of Crohn's disease. N Engl J Med 332:292-297, 1995.
97. Santos JV, Baudet JA, Casellas FJ, et al: Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results. J Clin Gastroenterol 20:207-210, 1995.
98. Feagan BG, McDonald JW, Rochon J, et al: Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 330:1846-1851, 1994.
99. Fluckiger SS, Schmidt C, Meyer A, et al: Pharmacokinetics of orally administered cyclosporine in patients with Crohn's disease. J Clin Pharmacol 35:681-687, 1995.
100. Fernandez-Benares F, Cabre E, Comas-Esteve M, et al: How effective is enterai nutrition in inducing remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J Parenter Enteral Nutr 19:356-364, 1995.
101. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta-analysis of enterai nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108:1056-1067, 1995.
102. Gorard DA, Hunt JB, Payne-James JJ, et al: Early response and subsequent relapse rates in Crohn's disease treated with elemental diet or prednisolone. A controlled trial. Gastroenterology 100:213A, 1991.
103. Malchow H, Steinhardt HJ, Lorents-Meyer H, et al: Feasibility and effectiveness of a defined-formula diet regime in treating active Crohn's disease. Scand J Gastroenterol 25:235-244, 1990.
104. Rigaud D, Cosnes J, Le Quintrec Y, et al: Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: Elemental versus polymeric diet. Gut 32:1492-1497, 1991.
105. Giaffer MH, North G, Holdsworth CD: Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 335:816-819, 1990.
106. Park R, Galloway A, Russell RJ: Double blind controlled trial of elemental and polymeric diets as primary therapy in active Crohn's disease. Eur J Gastroenterol Hepatol 3:483-490, 1991.
107. Roediger WE, Giles MB, Kaczmar A, et al: Does exclusion of enterai lipid assist remission in Crohn's disease? J Clin Gastroenterol 17:3841, 1993.
108. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 29:1309-1315, 1988.
109. Rombeau JL, Barot LR, Williamson CE, et al: Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel, disease. Am J Surg 143:139, 1982.
110. Brignola C, Belloni C, DeSimone G, et al: Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn's disease. Aliment Pharmacol Ther 7:275-280, 1993.
111. Mulder TP, van der Sluys Veer A, Verspaget HW, et al: Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol 9:472-477, 1994.
112. Summers RW, Switz DM, Sessions JT Jr, et al: National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 77:847-869, 1979.
113. Gendre JP, Mary JY, Florent C, et al: Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. Gastroenterology 104:435-439, 1993.
114. Messori A, Brignola C, Trallori G, et al: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 89:692-698, 1994.
115. Caprilli R, Andreoli A, Capurso L, et al: Oral mesalazine (5-aminosalicylic acid, Asacol) for the prevention of postoperative recurrence of Crohn's disease. Aliment Pharmacol Ther 8:35, 1994.
116. Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide as maintenance therapy for Crohn's disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110:45-51, 1996.
117. Rutgeerts P, Hiele M, Geboes K, et al: Prevention of clinical recurrence after ileal resection for Crohn's disease with metronidazole: A placebo controlled study. Gastroenterology 108:1617-1621, 1995.
118. Bouhnik Y, Lemann M, Mary JY, et al: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215-219, 1996.
119. Arora S, Katkov WN, Cooley J, et al: A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn's disease. Gastroenterology 102:591A, 1992.
120. Stange EF, Modigliani R, Pena AS, et al: European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European Group. Gastroenterology 109:774-782, 1985.
121. Lorenz R, Weber PC, Szimnau P, et al: Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease - a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med (suppl) 225:225-232, 1989.
122. Belluzzi A, Brignola C, Campieri M, et al: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334:1557-1560, 1996.
123. Sartor RB: Cytokines in intestinal inflammation: Pathophysiologic and clinical considerations. Gastroenterology, 106:533-539, 1994.
124. Cominelli F, Kam L: Inflammatory mediators of inflammatory bowel disease. Curr Opin Gastroenterol 9:534-543, 1993.
125. Dinarello CA, Gelland JA, Gelland SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829-1835, 1993.
126. van Dullemen HM, van Deventer SJ, Hommes DW, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimetic monoclonal antibody (cA2). Gastroenterology 109:129-135, 1995.
127. McCabe RP, Woody J, van Deventer S, et al: A multicenter trial of cA2 anti-TNF chimeric monadanal antibody in patients with active Crohn's disease. Gastroenterology 110:962S, 1996.
128. Targan SR, Rutgeerts P, Hanauer SB, et al: A multicenter trial of anti-tumor necrosis factor (TNF) antibody (cA2) for treatment of patients with active Crohn's disease. Gastroenterology 110:1026S, 1996.
129. Stack W, Mann S, Roy A, et al: The effects of CDP571, an engineered human IgG4 anti-TNFα antibody in Crohn's disease. Gastroenterology 110:1018S, 1996.
130. Evans RC, Clark L, Heath P, et al: Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Gastroenterology 110:905S, 1996.
131. Sands BE, Podolsky DK, Tremaine WJ, et al: Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 110:1108S, 1996.
132. de Vries JE: Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 27:537-541, 1995.
133. van Deventer SJH, Elson CO, Fedorak RN, et al: Safety, tolerance, pharmacokinetics and pharmacodynamics of recombinant interleukin-10 (SCH 52000) in patients with steroid refractory Crohn's disease. Gastroenterology 110:1034S, 1996.
134. Keith JC Jr, Sonis AL, Pfeiffer ST, et al: IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (Dayt) 12:79S-89S, 1994.
135. Bank S, Sninsky C, Robinson M, et al: Safety and activity evaluation of rhIl-11 in subjects with active Crohn's disease. Gastroenterology 112:927S, 1997.
136. Lerebours E, Bussel A, Modigliani R, et al: Treatment of Crohn's disease by lymphocyte apheresis: A randomized controlled trial. Gastroenterology 107:357-361, 1994.
137. Canva-Delcambre V, Jacquot S, Robinet E, et al: Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 10:721-727, 1996.
138. Wallace JL, Higa A, McKnight GW, et al: Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflammation 16:343-354, 1992.
139. Palmen MJ, Dijkstra CD, van der Ende MB, et al: Anti-CDllb/CD18 antibodies reduce inflammation in acute colitis in rats. Clin Exp Immunol 101:351-356, 1995.
140. Podolsky DK, Lobb R, King N, et al: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 92:372-380, 1993.
141. Yacyshyn B, Woloschuk B, Yacyshyn D, et al: Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease. Gastroenterology 112:1123A, 1997.
142. Madden MV, Forthing MJ, Nicholls RJ: Inflammation in ileal reservoirs: "Pouchitis." Gut 31:247-249, 1990.
143. Nygaard K, Bergan T, Bjorneklett A, et al: Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 29:462-467, 1994.
144. Winter TA, Dalton HR, Merrett MN, et al: Cyclosporin A retention enemas in refractory distal ulcerative colitis and "pouchitis." Scand J Gastroenterol 28:701-704, 1993.
145. Rutgeers P, Ghoos Y, Vantrappen G, et al: Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 11:199-206, 1981.
146. Bernstein LH, Frank MS, Brantit LJ, et al: Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79:357-365, 1980.
147. Brandt LJ, Bernstein LH, Frank MS, et al: Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 83:383-387, 1982.
148. Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 30:58-64, 1985.
149. Hanauer SB, Smith MB: Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 88:646-649, 1993.
150. Present DH, Lichtiger S: Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 39:374, 1994.